Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

PURPOSE: We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL). METHODS: HRQL was assessed with the European Organisation for...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockler, Martin R., Martin, Andrew J., Davis, Ian D., Dhillon, Haryana M., Begbie, Stephen D., Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy R., Pook, David W., Reaume, M. Neil, Sandhu, Shahneen, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G., Winter, Diana G., Yip, Sonia, Zhang, Alison Y., Zielinski, Robert R., Sweeney, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906451/
https://www.ncbi.nlm.nih.gov/pubmed/34928708
http://dx.doi.org/10.1200/JCO.21.00941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906451/
https://www.ncbi.nlm.nih.gov/pubmed/34928708
http://dx.doi.org/10.1200/JCO.21.00941

Ejemplares similares